Hepatitis C Virus Antibody Positive Cases in Multitransfused Thalassemic Patients in South of Iran

AUTHORS

Ahmad Akbari 1 , * , Mohammad Hadi Imanieh 2 , Mehran Karimi 2 , Hamid Reza Tabatabaee 2

1 Research Center of Thalassemia, Dastgheib Hospital, Shiraz University of Medical Sciences, [email protected], IR.IRAN

2 Professor of Pediatric Gastroenterology, Gastrointestinal Department, Shiraz University of Medical Sciences, IR.IRAN

How to Cite: Akbari A, Imanieh M, Karimi M, Tabatabaee H. Hepatitis C Virus Antibody Positive Cases in Multitransfused Thalassemic Patients in South of Iran, Hepat Mon. Online ahead of Print ; 7(2):63-66.

ARTICLE INFORMATION

Hepatitis Monthly: 7 (2); 63-66
Article Type: Research Article
Received: January 24, 2007
Accepted: August 18, 2007

Crossmark

CHEKING

READ FULL TEXT
Abstract

Background and Aims: Hepatitis C virus (HCV) infection is the common cause of liver disease among thalassemic patients who receive recurrent blood transfusion. Recent studies in Iran has shown a high prevalance of HCV among Iranian thalassemic patients, inspite of low HCV seroprevalence in general population. In this study we investigated the prevalence of new cases of hepatitis C and its risk factor in the group of thalassemia major patients.
Methods: This study was carried out in thalassemic ward of Shiraz University of Medical Sciences, southern Iran in year 2003. Cases were  interviewed using a standard questionnaire including demographic, clinical history and HCV related risk behaviors. Then 3 blood samples were investigated by serum marker of anti-HCV antiboby (anti-HCV Ab) via Eliza-3th method in times zero, 45 days and after 6 months follow-up.
Results: The mean age of patients were 15.2 |¡ |6.3 (1-36 years old) and the proportion of male to female 1 to 1. The rate of HCV antibody positivity in the first sample was 25%. All of the second and third blood samples were negative. There was significant correlation between age and being positive for anti-HCV Ab (P < 0.001) and also between being positive anti-HCV Ab and the time they began to receive blood transfusion. The patients who started blood transfusion before 1996 (the year we started screening program for blood donors in Blood Bank in Iran) had 12.5 times more risk for being positive for anti-HCV Ab (odds ratio = 12.5).
Conclusions: Our results approved the effect of screening program for blood donors in blood transfusion centers.

Keywords

HCV Thalassemia Blood Transfusion Blood Bank Iran

© 0, Author(s). This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.

Full Text

Full text is available in PDF

COMMENTS

LEAVE A COMMENT HERE: